NeueHealth, Inc. (NEUE) entered a merger agreement on December 23, 2024, to be taken private by New Enterprise Associates and a group of existing investors for a deal valued at about $1.3 billion, including debt.
As per the agreement, holders of NeueHealth common stock will receive $7.33 per share in cash, representing a 70.07% premium from the stock’s last close.
NeueHealth is a healthcare company providing affordable, high-quality care through owned clinics, partnerships, and support services, serving populations covered under the Affordable Care Act (ACA), Medicare, and Medicaid.
New Enterprise Associates (NEA) is a global venture capital firm that partners with entrepreneurs to build transformative businesses across various stages and sectors, managing over $25 billion in assets as of June 30, 2024. Founded in 1977, NEA invests in technology and healthcare companies from the seed stage through IPO, with a track record of more than 280 portfolio company IPOs and over 465 mergers and acquisitions.
The deal includes a 30-day “go-shop” period ending on January 23, allowing the company to consider competing proposals.
NeueHealth’s executive leadership team will continue in their roles upon completion of the deal and plan to roll over 100% of their equity interests into newly issued equity interests in the privately held company.
Certain stockholders of NeueHealth, including NEA and 12 existing NeueHealth investors who hold all the outstanding preferred stock, have agreed to roll over their investments as well by exchanging their common and preferred shares for newly issued equity in the privately held company. The existing secured loan facility with Hercules Capital will also remain in place.
NEA plans to fund the deal entirely with guaranteed equity financing.
New Enterprise Associates is purchasing NeueHealth for 0.03 times its sales.
For a deeper understanding of this M&A transaction, please refer to the Deal Metrics page here:
Deal Metrics for the acquisition of NeueHealth, Inc. (NEUE) by New Enterprise Associates
The Deal Metrics page for each merger or acquisition includes:
Disclaimer: Please do your own due diligence before buying or selling any securities mentioned in this article. We do not warrant the completeness or accuracy of the content or data provided in this article.
Editor’s Note: Baranjot Kaur contributed to this article